JP Morgan Chase
ALNY icon

JP Morgan Chase’s Alnylam Pharmaceuticals ALNY Stock Holding History

JP Morgan Chase’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,000
Closed -$3.79M – 7711
2026
Q1 		$3.79M Sell
12,000
-28,000
-70% -$9.53M ﹤0.01% 3583
2025
Q4 		$15.9M Buy
40,000
+38,900
+3,536% +$17.2M ﹤0.01% 2265
2025
Q3 		$502K Buy
+1,100
New +$448K ﹤0.01% 5041
2025
Q2 		– Sell
-8,800
Closed -$2.38M – 7042
2025
Q1 		$2.38M Buy
+8,800
New +$2.26M ﹤0.01% 3746
2024
Q3 		– Sell
-22,000
Closed -$5.35M – 7397
2024
Q2 		$5.35M Buy
22,000
+2,000
+10% +$316K ﹤0.01% 2989
2024
Q1 		$2.99M Hold
20,000
– – ﹤0.01% 3514
2023
Q4 		$3.83M Buy
+20,000
New +$3.41M ﹤0.01% 3319
2023
Q3 		– Sell
-7,500
Closed -$1.42M – 7438
2023
Q2 		$1.42M Hold
7,500
– – ﹤0.01% 3796
2023
Q1 		$1.5M Buy
+7,500
New +$1.58M ﹤0.01% 3748
2022
Q4 		– Sell
-12,800
Closed -$2.56M – 6511
2022
Q3 		$2.56M Sell
12,800
-71,300
-85% -$13.6M ﹤0.01% 3271
2022
Q2 		$12.3M Buy
84,100
+12,800
+18% +$1.82M ﹤0.01% 1988
2022
Q1 		$11.6M Sell
71,300
-121,200
-63% -$18.5M ﹤0.01% 2219
2021
Q4 		$32.6M Buy
+192,500
New +$35.8M ﹤0.01% 1445
2021
Q1 		– Sell
-10,000
Closed -$1.3M – 6031
2020
Q4 		$1.3M Buy
+10,000
New +$1.34M ﹤0.01% 3787
2019
Q3 		– Sell
-215,000
Closed -$15.3M – 5696
2019
Q2 		$15.3M Buy
+215,000
New +$16.5M ﹤0.01% 1768
2018
Q4 		– Sell
-30,000
Closed -$2.63M – 5666
2018
Q3 		$2.63M Buy
30,000
+3,000
+11% +$302K ﹤0.01% 3263
2018
Q2 		$2.66M Hold
27,000
– – ﹤0.01% 3179
2018
Q1 		$3.22M Buy
+27,000
New +$3.48M ﹤0.01% 2929

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase's ALNY Position: Q2 2026 in Review

JP Morgan Chase reduced its Alnylam Pharmaceuticals (ALNY) stake by 58% in Q2 2026, selling an estimated $1.1B and leaving 2,675,517 shares worth $785M. The position accounts for 0.04% of the portfolio, ranked #331.

JP Morgan Chase first reported a position in ALNY in Q2 2013 and has held it in 53 quarters since. The position peaked at $2.07B in Q3 2025. 791 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • JP Morgan Chase held 2,675,517 shares of Alnylam Pharmaceuticals worth $785M as of Q2 2026.
  • JP Morgan Chase sold 3,648,235 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.1B.
  • Alnylam Pharmaceuticals made up 0.04% of JP Morgan Chase's portfolio in Q2 2026, its #331 holding.
  • JP Morgan Chase first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • JP Morgan Chase's Alnylam Pharmaceuticals position peaked at $2.07B in Q3 2025.
  • 791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.